Validation of the PANAMA-Score for Survival and Benefit of Adjuvant Therapy in Patients with Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX.
Rompen IF, Stoop TF, van Roessel S, van Veldhuisen E, Janssen QP, Alseidi A, Balduzzi A, Balzano G, Berrevoet F, Bonds M, Busch OR, Butturini G, Javed AA, Del Chiaro M, Conlon KC, Falconi M, Frigerio I, Fusai GK, Gagnière J, Griffin O, Hackert T, Sparrelid E, Halimi A, Labori KJ, Malleo G, Marino MV, Mortensen MB, Nikov A, Lesurtel M, Keck T, Kleeff J, Pandé R, Pfeiffer P, Pietrasz D, Roberts KJ, Sa Cunha A, Salvia R, Strobel O, Tarvainen T, van Laarhoven HWM, Koerkamp BG, Loos M, Michalski C, Besselink MG, Hank T.
Rompen IF, et al. Among authors: roberts kj.
Ann Surg. 2025 Jan 31. doi: 10.1097/SLA.0000000000006650. Online ahead of print.
Ann Surg. 2025.
PMID: 39886770